Skip to main content

Dexrazoxane Injection Shortage

Last Updated: August 13, 2020
Status: Resolved

Products Affected - Description
    • Zinecard injection, Pfizer, 250 mg, vial, 1 count, NDC 00013-8717-62 - discontinued
    • Zinecard injection, Pfizer, 500 mg, vial, 1 count, NDC 00013-8727-89 - discontinued
Reason for the Shortage
    • Cumberland Pharmaceuticals relaunched Totect in late-July 2017.
    • Fosun Pharma has dexrazoxane available.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has dexrazoxane available.
    • Pfizer discontinued Zinecard in June 2020.
Available Products
    • Totect kit, Cumberland Pharmaceuticals, 500 mg, vial, (only for extravasation injuries) 1 count, NDC 66220-0110-01
    • Dexrazoxane injection, Fosun Pharma, 500 mg, vial, 1 count, NDC 72266-0101-01
    • Dexrazoxane injection, Hikma, 250 mg, vial, 1 count, NDC 00143-9247-01
    • Dexrazoxane injection, Hikma, 500 mg, vial, 1 count, NDC 00143-9248-01
    • Dexrazoxane injection, Mylan Institutional, 250 mg, vial, 1 count, NDC 67457-0207-25
    • Dexrazoxane injection, Mylan Institutional, 500 mg, vial, 1 count, NDC 67457-0208-50

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated August 13, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 30, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer